title: Emerging drugs for acromegaly.
abstract: BACKGROUND
  Acromegaly is a rare disease that severely impacts patients' health all the while, being a slowly progressing illness. In the past decades, advancements in treatment modalities, especially development of new drugs, as well as focused guidelines has improved management of acromegaly. Still, many patients are considered not sufficiently treated and there remains an ongoing need for further development.
  
  
  METHODS
  This article reviews new medical treatments currently under clinical investigation (such as pasireotide, oral octreotide and somatoprim) and under experimental development (such as octreotide implants, CAM2029 and ATL-1103).
  
  
  CONCLUSIONS
  As it seems unlikely that one single agent may achieve cure in 100% of cases, there is an urgent need for new agents that help patients where current medication fails. Imperatively, this means we have to improve our understanding of the underlying pathogenetic and molecular mechanisms.
authors.affiliation: Klinikum der Universität München, Medizinische Klinik und Poliklinik IV , Ziemssenstr. 1, 80336 München , Germany +49 0 89 5160 2111 ; +49 0 89 5160 2194 ; sylvere.stoermann@med.uni-muenchen.de.
authors.forename: Sylvère
authors.initials: S
authors.lastname: Störmann
authors.forename: Jochen
authors.initials: J
authors.lastname: Schopohl
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000818:Animals; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: C420459:PTR 3173; D013004:Somatostatin; C517782:pasireotide; D015282:Octreotide